TY  - JOUR
AU  - Ayala Díaz, Rosa María
AU  - Martínez López, Joaquín
PY  - 2023
DO  - 10.1002/jha2.685
SN  - 2688-6146
SN  - 2688-6146
UR  - https://hdl.handle.net/20.500.14352/103316
T2  - eJHaem
AB  - This phase Ib, non-randomized, open-label study evaluates the safety and tolerability of ruxolitinib in combination with nilotinib and prednisone in patients with naïve or ruxolitinib-resistant myelofibrosis (MF). A total of 15 patients with primary...
LA  - eng
M2  - 401
PB  - wiley
KW  - Combination therapy
KW  - Nilotinib
KW  - Prednisone
KW  - Ruxolitinib
KW  - Myelofibrosis
TI  - Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
TY  - journal article
VL  - 2023
ER  -